Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Miguel Guerra-RodríguezFarmacología Molecular y Traslacional (BIOPharm), Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Paseo Blas Cabrera Felipe Físico s/n, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-0047-1131
Priscila López-RojasDepartamento de Química Orgánica, Instituto Universitario de Bio-Orgánica Antonio González (IUBO AG), Universidad de La Laguna (ULL), Avda. Astrofísico Fco. Sánchez 2, 38206 La Laguna, Spain.
Ángel AmestyDepartamento de Química Orgánica, Instituto Universitario de Bio-Orgánica Antonio González (IUBO AG), Universidad de La Laguna (ULL), Avda. Astrofísico Fco. Sánchez 2, 38206 La Laguna, Spain.
Haidée Aranda-TavíoFarmacología Molecular y Traslacional (BIOPharm), Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Paseo Blas Cabrera Felipe Físico s/n, 35016 Las Palmas de Gran Canaria, Spain.
Yeray Brito-CasillasFarmacología Molecular y Traslacional (BIOPharm), Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Paseo Blas Cabrera Felipe Físico s/n, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-0707-7444
Ana Estévez-BraunDepartamento de Química Orgánica, Instituto Universitario de Bio-Orgánica Antonio González (IUBO AG), Universidad de La Laguna (ULL), Avda. Astrofísico Fco. Sánchez 2, 38206 La Laguna, Spain.ORCID 0000-0001-5279-7099
Leandro Fernández-PérezFarmacología Molecular y Traslacional (BIOPharm), Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Paseo Blas Cabrera Felipe Físico s/n, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0001-7802-465X
Borja GuerraFarmacología Molecular y Traslacional (BIOPharm), Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Paseo Blas Cabrera Felipe Físico s/n, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0003-4355-5682
Carlota RecioFarmacología Molecular y Traslacional (BIOPharm), Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Paseo Blas Cabrera Felipe Físico s/n, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-8832-2826
Universidad de Las Palmas de Gran Canaria · ESUniversidad de La Laguna · ES
Funding
Agencia Canaria de Investigación, Innovación y Sociedad de la Información ACIISI, Pro ID 2017010071, Pro ID 2021010037Alfredo Martin-Reyes Foundation (Arehucas)-FICIC N/ACabildo de Tenerife Agustín de Betancourt ProgramEuropean Regional Development Fund (FEDER) N/AMinisterio de Ciencia e Innovación, Ayuda Juan de la Cierva Incorporación IJC2018-035193-IMinisterio de Ciencias, Innovación y Universidades MICINN, RTI2018-094356-B-C21Ministerio de Economía y Competitividad SAF 2015-65113-C2-1-R; SAF 2015-65113-C2-2-R; CEI2018-23/ACIISI; CEI2019-08/ACIISI
6 · The paper itself
Abstract
Tamoxifen improves the overall survival rate in hormone receptor-positive breast cancer patients. However, despite the fact that it exerts antagonistic effects on the ERα, it can act as a partial agonist, resulting in tumor growth in estrogen-sensitive tissues. In this study, highly functionalized 5-hydroxy-2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery of Highly Functionalized 5-hydroxy-2 · full record | OpenQuestion